Read More

ThermoGenesis Reported in Filing Tuesday It Received a Conversion Notice From Boyalife Asset Holding II to Convert a Total of $3M of the Outstanding Balance of the Second Amended and Restated Convertible Promissory Note Issued to Boyalife on April 16,…

On June 28, 2022, ThermoGenesis Holdings, Inc. (the "Company") received a conversion notice from Boyalife Asset Holding II, Inc.("Boyalife") to convert a total of $3,000,000 of the outstanding balance of the Second Amended and Restated Convertible Promissory Note issued by the Company to Boyalife on April 16, 2018, as amended by Amendment No 1 thereto dated March 4, 2022 (as amended, the "Note").

THMO

Read More

Immutep Announced Tuesday it was Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number7074341) entitled "Anti- LAG-3 Antibodies" by the Japanese Patent Office.

IMMP